Application of neuraminidase inhibitor in the preparation of medicine for treating myocarditis
A neuraminidase inhibitor technology, applied in the field of medicine, can solve problems such as neuraminidase inhibitor myocarditis
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Examples
Embodiment 1
[0015] Embodiment 1: to the therapeutic effect of viral myocarditis
[0016] 1. Test method
[0017] 1. Animal grouping, modeling and administration
[0018] 5-week-old male BALB / c mice were randomly divided into 3 groups, namely control group, model group, oseltamivir phosphate treatment group (OS group), zanamivir treatment group (ZA group), 20 in each group . The control group was intraperitoneally inoculated with 0.1mL Eagle solution without Coxsackievirus B3 (CVB3), and the model group, OS group and ZA group were intraperitoneally injected with 0.1mL containing 1×10 2 TCID 50 The Eagle solution of CVB3 replicated the viral myocarditis model. From the day of inoculation, the OS group was given 10 mg / kg / d oseltamivir phosphate (p.o.), and the ZA group was given 0.4 mg / kg / d zanamivir (i.v.) for 2 consecutive weeks. The control group and model group were given an equal volume of vehicle.
[0019] CVB3 was passaged in HeLa cells, after freezing and thawing and centrifugi...
Embodiment 2
[0035] Example 2: Therapeutic effect on autoimmune myocarditis
[0036] 1. Test method
[0037] 1. Animal grouping, modeling and administration
[0038] 5-week-old male BALB / c mice were randomly divided into 3 groups, namely control group, model group, oseltamivir phosphate treatment group (OS group), zanamivir treatment group (ZA group), 20 in each group . The model group, OS group and ZA group were subcutaneously injected with porcine myocardial myosin (200 μg / cause, about 20 μL / cause) and the same volume of complete Freund’s adjuvant in the groin on the 1st and 5th day respectively, and the control group was injected with the same volume of vehicle and complete Freund's adjuvant. From the day of inoculation, the OS group was given 10 mg / kg / d oseltamivir phosphate (p.o.), and the ZA group was given 0.4 mg / kg / d zanamivir (i.v.) for 3 consecutive weeks; the control group and the model group were given solvent.
[0039] 2. Index detection
[0040] 2 hours after the last a...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com